Author

Laura Turunen

University of HelsinkiORCID 0000-0003-0274-4794Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Krister WennerbergiD· 3 shared Aleksandr IanevskiiD· 2 shared Tero A. AittokallioiD· 2 shared Anil Kumar GiriiD· 1 shared Anna Näätänen· 1 shared Bishwa R. GhimireiD· 1 shared Caroline Akemi HeckmaniD· 1 shared Chiara FacciottoiD· 1 shared

Activity by Year

2016-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersSystems Biology

Krister WennerbergORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 17, 2026

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface

Jonas Bouhlal, Emmi Jokinen, Petra Johanna Nygren…·Satu M. Mustjoki

The paper identifies drugs that rewiring the cancer-immune interface by enhancing NK cell function and tumor susceptibility through multimodal screening approaches.

DOI 10.64898/2026.04.13.717771

humanbulk RNA-seq

𝕏 PostBluesky

Systems BiologyScience AdvancesPeer-reviewedFeb 19, 2021

Patient-tailored design of AML cell subpopulation-selective drug combinations

Aleksandr Ianevski, Jenni Lahtela, Komal Kumar Javarappa…·Tero A. Aittokallio

This paper develops a computational-experimental approach to design patient-specific drug combinations for AML that are synergistic and minimally toxic.

43 citationstop 4%

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 6, 2019

Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin

Chiara Facciotto, Julia Casado, Laura Turunen…·Sampsa Hautaniemi

This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.

DOI 10.1101/538199

humanexperimental assay

𝕏 PostBluesky

Systems BiologybioRxivMay 5, 2016

Methods for High-Throughput Drug Combination Screening and Synergy Scoring

Liye He, Evgeny Kulesskiy, Jani Saarela…·Jing Tang

The paper develops an experimental-computational pipeline for high-throughput drug combination screening and synergy scoring in cancer cells.

DOI 10.1007/978-1-4939-7493-1_17

experimental assaydrug response / drug discovery

𝕏 PostBluesky